Filter By Category
Archives
Share on -
ALPELISIB
Generic Name: ALPELISIB
ABSTRACT -
Alpelisib inhibits mutant PI3K-alpha signalling and is used in selected PIK3CA-altered cancers with indication-specific companion diagnostics and combination therapy.
DOSAGE -
Use the current locally approved prescribing information where a product is authorized. For investigational products, dose, route, schedule, premedication, and dose modifications must come only from the applicable clinical-trial protocol. No dose should be selected from this summary.
SIDE EFFECTS–
- High blood glucose
- Rash
- Diarrhoea
- Nausea
- Reduced appetite
- Pneumonitis
ALLRGIC REACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
- Hives or a rapidly spreading rash
- Swelling of the face, lips, tongue, or throat
- Wheezing, breathing difficulty, or sudden dizziness
- Severe blistering, mucosal lesions, or anaphylaxis
DRUG INTERACTIONS–
- CYP3A inducers may lower exposure
- BCRP inhibitors may increase exposure
- Medicines affecting glucose require close review
PREAUTIONS–
- Monitor fasting glucose, HbA1c, skin, and pulmonary symptoms
- Manage diarrhoea and dehydration promptly
WARNINGS –
- Severe hyperglycaemia, serious skin reactions, pneumonitis, and severe diarrhoea can occur
Share on -
. Developed by